U.S. health systems are quietly incurring millions of dollars in hidden costs from so-called “free trials” of artificial intelligence (AI) tools, according to industry analyses reported by MedCity News.
In what is a multi-million dollar version of the saying “no such thing as a free lunch” AI pilots in healthcare are proving to be another expensive administrative cost to the system — with the check, as always, picked up by the end consumer.
The expenses accrue quickly once decision-makers greenlight their teams to dive into trials following impressive product demonstrations.
The resulting organizational overhead, dedicated staff time, and accumulating opportunity costs mean that even failed projects come with a steep price tag.
A 2022 report from Stanford found that AI models marketed as “free”—but requiring custom data extraction or further training to be suitable for clinical use—can cost upward of $200,000.
When this price is multiplied across the dozens of trials common in large health systems, the cumulative cost of failure can quickly balloon into the millions.
This financial burden is set against a backdrop of extraordinarily high failure rates. The Massachusetts Institute of Technology’s (MIT) State of AI in Business 2025 report identified that 95 percent of generative AI pilots fail.
This failure is often attributed to the “GenAI Divide,” where generic tools, though impressive in a demo, collapse when integrated into complex, real-world healthcare workflows. When these expensive experiments fail to deliver, trust in AI erodes, reinforcing the perception that the technology is more hype than help.
The core issue is not necessarily flawed technology—AI, when deployed thoughtfully, has been shown to reduce administrative burden and lower clinician burnout, according to the American Medical Association.
Instead, the failures stem from a critical lack of discipline and structure in implementation, turning pilots into “exercises in hope rather than strategy” according to Demetri Giannikopoulos, Chief Innovation Officer at Rad AI, a specialist AI healthcare company.
Giannikopoulos argues that to reverse this costly trajectory, leaders must implement rigor. This structure begins with discipline in design, requiring leaders to define who the tool is for, what problem it solves, and above all, why they need it. This guiding principle is essential for successful measurement and adoption, avoiding confusion about the mission which comes with an inevitable price tag.
Secondly he stresses that every pilot must start with a specific and measurable definition of success tied to organizational priorities, such as reducing report turnaround time or improving patient access.
Finally, organizations require discipline in partnerships. Experts caution against defaulting to the largest or cheapest vendor, noting that generic Gen AI tools frequently fail due to their incompatibility with complex healthcare environments.
Success is more likely when choosing partners who deeply understand the specific clinical domain, help define outcomes, and share accountability for results.